NBTX stock forecast, quote, news & analysis
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients... Show more
Why Nanobiotix (NBTX) Stock Is Up +12% in the Last 30 Days
Key Takeaways
- Nanobiotix (NBTX) shares advanced roughly 12% over the trailing 30 days, climbing from about $25.75 to near $28.92.
- The gain reflects a sharp rebound off a mid-October trough near $21, though the stock remains down approximately 26% over the last quarter.
- Final Phase 1 data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026, showed a 41.7% overall response rate and supported the recovery.
- The appointment of Arnd Christ as chief financial officer and continued progress on the Johnson & Johnson-partnered pipeline reinforced the narrative.
- As a clinical-stage, pre-revenue biotechnology company, Nanobiotix remains dependent on milestone payments, financing, and pipeline execution.
- For more detail on valuation and expectations, explore the company’s Price Targets, Earnings, and Forecast pages.
- To monitor AI-driven trading activity across the market, explore Trending AI Robots.
Nanobiotix (NBTX) Company Overview and Market Position
Nanobiotix is a Paris, France-based late-stage clinical biotechnology company pioneering physics-based nanotherapeutics. Its lead candidate, NBTXR3, is a sterile suspension of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy inside tumor cells while limiting exposure to surrounding healthy tissue. The asset, now referred to as JNJ-1900, is licensed to Johnson & Johnson (JNJ), which sponsors ongoing clinical development, including the pivotal NANORAY-312 study in head and neck cancer and the CONVERGE Phase 2 study in non-small cell lung cancer.
Beyond NBTXR3, the company holds more than 30 patent families spanning three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders. Nanobiotix is listed on Euronext Paris and on the Nasdaq Global Select Market under the ticker NBTX. Investors follow the stock closely for clinical data readouts, regulatory milestones, and the company’s partnership economics with Johnson & Johnson.
Nanobiotix (NBTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, NBTX advanced approximately 12%, moving from a closing price near $25.75 to about $28.92. The move was far from linear: the stock slipped to a trough near $21 in mid-October before rebounding sharply toward $34 in late October and then pulling back in early November.
The longer quarterly picture tells a different story. Over the last three months, the stock is down roughly 26%, having traded near $39 in early August before a prolonged slide into mid-October. The recent 30-day recovery therefore represents a partial retracement of a broader multi-month decline rather than a return to prior highs.
What Drove NBTX Stock Price in the Last 30 Days
The most significant catalyst in the recent window was clinical data. On October 24, 2026, Nanobiotix announced final data from the Phase 1 Study 1100 evaluating JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in patients with anti-PD-1-resistant advanced primary cutaneous melanoma. In 24 heavily pre-treated patients, investigators reported a 41.7% overall response rate, a median progression-free survival of 6.9 months, and a median overall survival of 17.8 months, alongside an acceptable safety profile. The data were presented at the ESMO 2026 annual meeting.
The stock’s late-October advance coincided with this data flow and broader optimism around the company’s oncology pipeline. Earlier in the month, on October 1, the company announced the appointment of Arnd Christ as chief financial officer, bringing more than two decades of public biotech leadership experience. The subsequent pullback from late-October highs into early November occurred as some investor commentary raised questions about the timing of the Phase 3 program and the priority of lender obligations.
What Drove NBTX Stock Performance Over the Last Quarter
The last quarter has been defined by elevated volatility rather than a single event. Through September and early October, the stock trended lower amid the absence of a near-term Phase 3 readout, dilution considerations following a May 2026 follow-on offering, and broader risk-off sentiment across the clinical-stage biotechnology sector.
That weakness was partially reversed in late October as the company delivered a series of supportive updates, including full-cohort Phase 1 results in recurrent non-small cell lung cancer and the ESMO melanoma data. The partnership with Johnson & Johnson remains the central long-term driver, with the NANORAY-312 pivotal study in cisplatin-ineligible head and neck cancer serving as the key value-inflection point investors are watching.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI-powered trading bots. While Tickeron offers hundreds of automated bots that trade across thousands of tickers, only the top-performing and most relevant strategies appear in this section. The featured bots vary by trading strategy, timeframe, and performance metrics, giving users a filtered view of currently active, higher-conviction signals. The page is designed to help traders and investors identify patterns and momentum across the market. For those interested in systematic, data-driven approaches, exploring the Trending AI Robots section can provide additional context on automated market activity.
NBTX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important milestones center on the Johnson & Johnson-sponsored pipeline. The pivotal NANORAY-312 Phase 3 study in cisplatin-ineligible head and neck cancer remains the primary catalyst; the company and its partner have modified the study to conduct the final analysis sooner with fewer events, which could affect the timing of a potential readout. Additional data from the CONVERGE Phase 2 study in non-small cell lung cancer and further updates from Study 1100 will also shape sentiment.
Financially, Nanobiotix reported cash and cash equivalents of €110.9 million as of June 30, 2026, with the company projecting a cash runway into 2029. Investors will monitor milestone and revenue recognition under the Johnson & Johnson agreement, capital allocation, and any financing activity. Macroeconomic conditions, biotech sector sentiment, and interest-rate expectations remain relevant external factors for this clinical-stage name.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NBTX in upward trend: price rose above 50-day moving average on November 09, 2026
NBTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +7.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 53 cases where NBTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.498). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology